YB-3−17 is a dual-target compound that effectively and selectively inhibits mTOR with an IC50 of 0.22 nM, while promoting GSPT1 degradation with an IC50 of 5 nM, leading to substantial tumor growth inhibition both in vitro and in vivo. It also exhibits significant antiproliferative activity in glioblastoma models.

YB-3−17 is a dual-target compound that effectively and selectively inhibits mTOR with an IC50 of 0.22 nM, while promoting GSPT1 degradation with an IC50 of 5 nM, leading to substantial tumor growth inhibition both in vitro and in vivo. It also exhibits significant antiproliferative activity in glioblastoma models.

YB-3−17 is a dual-target compound that effectively and selectively inhibits mTOR with an IC50 of 0.22 nM, while promoting GSPT1 degradation with an IC50 of 5 nM, leading to substantial tumor growth inhibition both in vitro and in vivo. It also exhibits significant antiproliferative activity in glioblastoma models.

JNJ-28583113 is a potent, brain-penetrant antagonist of TRPM2 with an IC50 of 126 nM that protects cells from oxidative stress-induced death and morphological changes. It also inhibits microglial cytokine release in response to pro-inflammatory stimuli and promotes GSK3α/β phosphorylation.

OGT 2115 is a potent, cell-permeable and orally active inhibitor of heparanase and Angiogenesis with an IC50 of 0.4 μM and 7.5 μM respectively. It exhibits potent anti-angiogenic properties.

JNJ-28583113 is a potent, brain-penetrant antagonist of TRPM2 with an IC50 of 126 nM that protects cells from oxidative stress-induced death and morphological changes. It also inhibits microglial cytokine release in response to pro-inflammatory stimuli and promotes GSK3α/β phosphorylation.

JNJ-28583113 is a potent, brain-penetrant antagonist of TRPM2 with an IC50 of 126 nM that protects cells from oxidative stress-induced death and morphological changes. It also inhibits microglial cytokine release in response to pro-inflammatory stimuli and promotes GSK3α/β phosphorylation.

AT791 is a potent and orally bioavailable inhibitor of TLR7 and TLR9 with an IC50 of 3.33 μM and 0.04 μM, respectively, in human embryonic kidney cells and also inhibits DNA-TLR9 interaction in vitro.

JNJ-28583113 is a potent, brain-penetrant antagonist of TRPM2 with an IC50 of 126 nM that protects cells from oxidative stress-induced death and morphological changes. It also inhibits microglial cytokine release in response to pro-inflammatory stimuli and promotes GSK3α/β phosphorylation.

AT791 is a potent and orally bioavailable inhibitor of TLR7 and TLR9 with an IC50 of 3.33 μM and 0.04 μM, respectively, in human embryonic kidney cells and also inhibits DNA-TLR9 interaction in vitro.